The Pharmaletter

One To Watch

fennec_pharma_company

Fennec Pharma

A specialty pharmaceutical company focused on the development of Pedmark (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients.

As of December of 2021, the US Food and Drug Administration had twice rejected Fennec's attempts to gain approval for Pedmark due to production deficiencies.

Pedmark is the only drug candidate under clinical development in the US firm’s pipeline. In Europe, Fennec has submitted for marketing authorization to use the therapy under the trade name Pedmarqsi.

Want to Update your Company's Profile?


More Fennec Pharma news >